Neurocrine Biosciences, Inc.
NBIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $13,953,772 | $12,443,310 | $11,026,820 | $13,650,000 |
| - Cash | $340,200 | $264,000 | $194,100 | $233,000 |
| + Debt | $428,400 | $439,100 | $447,500 | $455,100 |
| Enterprise Value | $14,041,972 | $12,618,410 | $11,280,220 | $13,872,100 |
| Revenue | $794,900 | $687,500 | $572,600 | $627,700 |
| % Growth | 15.6% | 20.1% | -8.8% | – |
| Gross Profit | $780,900 | $676,200 | $563,400 | $618,400 |
| % Margin | 98.2% | 98.4% | 98.4% | 98.5% |
| EBITDA | $299,500 | $152,900 | $31,300 | $181,700 |
| % Margin | 37.7% | 22.2% | 5.5% | 28.9% |
| Net Income | $209,500 | $107,500 | $7,900 | $103,100 |
| % Margin | 26.4% | 15.6% | 1.4% | 16.4% |
| EPS Diluted | 2.04 | 1.06 | 0.08 | 1 |
| % Growth | 92.5% | 1,225% | -92% | – |
| Operating Cash Flow | $227,500 | $102,000 | $64,800 | $242,500 |
| Capital Expenditures | -$13,200 | -$12,500 | -$10,700 | -$7,300 |
| Free Cash Flow | $214,300 | $89,500 | $54,100 | $235,200 |